Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is
effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma (HCC)
after failure or intolerance to Sorafenib. Patients with HCC with or without cirrhosis and
with good liver functions are eligible. Only those who can not benefit from treatment for
which efficacy is demonstrated are eligible.
These patients are usually proposed either best standard of care (BSC) or participation to
clinical trials. Patients eligible for the RELIVE study will receive either DT at 20 mg/m2 or
DT at 30 mg/m2 or the BSC.